Hear about opportunities for improving population health outcomes in cardiorenal metabolic syndrome, including clinical and payer considerations of emerging diabetes treatments.
This AJMC® Profiles in Care provides an in-depth look into the results of the outcomes-based agreement between Boehringer Ingelheim and Highmark Inc.
December 1st 2021, 3:00pm
Results of a cohort study showed that transfeminine individuals may be at a higher risk for type 2 diabetes (T2D) compared with cisgender females, but revealed little evidence that gender-affirming hormone therapy impacts diabetes risk.
November 29th 2021, 6:35pm
Data showed differences in statin use to prevent cardiovascular disease among Finnish patients with type 2 diabetes.
November 22nd 2021, 4:00pm
CMS' introduction of 3 new electronic clinical quality measures, 2 of which are focused on inpatient glycemic management, signal a strong commitment to shine a light on this often-overlooked area, according to the chief medical officer at Glytec.
November 16th 2021, 5:30pm
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains the Health Equity Now initiative and how it shines a light on health disparities.
November 10th 2021, 5:00pm
Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.
This study presents challenges of implementing the CDC-approved Diabetes Prevention Program for Medicare beneficiaries at a large, integrated health care delivery system.
November 8th 2021, 4:40pm
Results of a cross-sectional study detail characteristics among women with polycystic ovary syndrome (PCOS) who develop type 2 diabetes.
November 3rd 2021, 12:00pm
Results of a longitudinal study indicate community food accessibility factors may impact type 2 diabetes risk among veterans.
October 31st 2021, 3:00pm
New research underscores racial/ethnic diabetes disparities in the United States.
October 29th 2021, 5:15pm
As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
.jpeg?w=200&fit=crop&auto=format)
